Evidence map›Paper›PMID 37534251›Full record

ArticleFrontiers in oncology2023

Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T

Lili Wu, Yaolin Xu, Yuhong Zhou, Zhaochong Zeng, Yue Fan, Dansong Wang, Wenchuan Wu, Xi Guo, Minzhi Lv, Yuxiu Ouyang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lili WuDepartment of Radiotherapy, Zhongshan Hospital Fudan University, Shanghai, China.
Yaolin XuDepartment of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China.
Yuhong ZhouDepartment of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, China.
Zhaochong ZengDepartment of Radiotherapy, Zhongshan Hospital Fudan University, Shanghai, China.
Yue FanDepartment of Traditional Chinese Medicine, Zhongshan Hospital Fudan University, Shanghai, China.
Dansong WangDepartment of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China.
Wenchuan WuDepartment of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China.
Xi GuoDepartment of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, China.
Minzhi LvDepartment of Biostatistics, Zhongshan Hospital Fudan University, Shanghai, China.
Yuxiu OuyangDepartment of Abdominal Tumor Radiotherapy, Guangdong Province Zhongshan City People's Hospital, Zhongshan, Guangdong, China.
Shisuo DuDepartment of Radiotherapy, Zhongshan Hospital Fudan University, Shanghai, China.
Wenhui LouDepartment of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: While adjuvant chemotherapy has been established as standard practice following radical resection of pancreatic ductal adenocarcinoma (PDAC), the role of adjuvant radiation therapy (RT) and which patients may benefit remains unclear. Methods: This retrospective study included PDAC patients who received pancreatic surgery from April 2012 to December 2019 in Zhongshan Hospital Fudan University. Patients with carcinoma Results: A total of 399 patients were finally included, 93 of them receiving adjuvant chemoradiotherapy (C+R+) and 306 of them receiving chemotherapy only. Patients in C+R+ group were more likely to be male patients with T3-4 disease. Lymph node metastases was the only negative prognostic factor associated with overall survival (OS). Additional adjuvant RT was not associated with an OS benefit both before and after PSM. Surprisingly, a trend towards improved OS with RT among patients with either T4, N2 disease or R1 resection becomes significant in patients alive more than 1 year after surgery. Conclusion: Adjuvant RT was not associated with an OS benefit across all patients, though did show a possible OS benefit for the subgroup with T4N2 disease or R1 resection at 1 year after surgery.

Indexed as

chemotherapyoverall survivalpancreatic ductal adenocarcinomaradiotherapysurgery

Identifiers

PMID37534251
PMCPMC10391548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.